Dario Altieri

Dario Carlo Altieri, M.D., is an American physician and scientist working as director of the National Cancer Institute-designated Ellen and Ronald Caplan Cancer Center at The Wistar Institute in Philadelphia.[1] Since 2015, he has served as the President and Chief Executive Officer (CEO) of The Wistar Institute.[2] In addition, he co-founded the Cancer Biology Training Consortium and the Pancreatic Cancer alliance in 2005.[2]

Dario Carlo Altieri
OccupationResearcher

Trained in internal medicine with a postgraduate specialty degree in clinical and experimental hematology, Altieri focuses on the role of mitochondria in cancer and how exploitation of multiple mitochondrial functions enables tumor cell proliferation, evasion from multiple forms of cell death, and a heightened ability to metastasize.[2][3] In addition to focusing on mitochondrial exploitation in cancer, he is the discoverer of the survivin gene, a fundamental regulator of cell division and cell survival universally over-expressed in cancer and a validated therapeutic target.[3]

The author of over 250 peer-reviewed scientific articles, and a named inventor on 13 issued patents, Altieri maintains a federally funded laboratory and is the winner of an Outstanding Investigator Award (OIA) from the National Cancer Institute in 2017.[4]

Prior to joining Wistar, Altieri completed his academic career as a Professor with Tenure in the Department of Pathology, Boyer Center for Molecular Medicine at Yale University School of Medicine, and was founding Chair of the Department of Cancer Biology at the University of Massachusetts Medical School.[2][3]

Research

His research has focused on Inhibitors of Apoptosis (IAP), a family of genes essential for proliferation and survival of cells. His work has identified survivin, one of these IAP genes, is over-produced in almost every human cancer, and his team is currently studying the biology of survivin and how it could be used to develop treatments for cancer.[5][6][7]

Altieri has also been involved in the development of gamitrinib, a Hsp90 inhibitor that was shown to disable the activity of mitochondria in cancerous cells.

In 2013, Altieri and his team received a $1.5 million grant from the United States Department of Defense to prepare the drug for human trials.[8][9] Prior to joining Wistar, Altieri was the founding chair of the Department of Cancer Biology at the University of Massachusetts Medical School. He also co-founded the Cancer Biology Training Consortium and the Pancreatic Cancer alliance in 2005.[10]

Further reading
  • "Dario C. Altieri Inventions, Patents and Patent Applications". Justia Patents Search. 2021-12-23. Retrieved 2023-03-15.<
  • "A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer - Full Text View". ClinicalTrials.gov. 2021-04-01. Retrieved 2023-03-15.

References
  1. "Cancer Biologist Dario Altieri to Lead the Wistar Institute Cancer Center". The Wistar Institute. Retrieved 11 February 2014.
  2. "Dario C. Altieri: Chief Executive Officer of Wistar Institute". The University of Pennsylvania. Retrieved 2 March 2015.
  3. "Gene "survivin" inhibits cell death" (PDF). Yale Cancer Center. Retrieved 2023-03-15.
  4. "The Wistar Institute president receives NCI award". Healio. 2017-08-27. Retrieved 2023-03-15.
  5. "Dario C. Altieri, M.D." The Wistar Institute. Retrieved 28 January 2014.
  6. "Thrivin' (not just survivin') in Philadelphia". The Journal of Clinical Investigation. Retrieved 28 January 2014.
  7. "Emerging Research Fronts - 2009". ScienceWatch. Retrieved 11 February 2014.
  8. "Wistar Receives $1.5 Million Department of Defense Grant To Ready Potential Prostate Drug For Clinical Use". The Wistar Institute. Retrieved 28 January 2014.
  9. "Combinatorial Drugs Target Cancer Cell Mitochonndria". biotechdaily.com. Retrieved 11 February 2014.
  10. "Cancer Biologist Dario Altieri to Lead the Wistar Institute Cancer Center". The Wistar Institute. Retrieved 28 January 2014.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.